Dr. Wyatt is an Associate Professor in Urologic Sciences at the University of British Columbia and serves as a Senior Scientist at both the Vancouver Prostate Centre and BC Cancer. He earned his DPhil in Genetics from the University of Oxford.
Dr. Wyatt’s research focuses on linking genomic and epigenomic alterations to patient outcomes in advanced prostate and bladder cancers, with the goal of developing clinical biomarkers from these findings. His team has pioneered laboratory and computational methods to analyze genomic and epigenomic features in plasma circulating tumor DNA (ctDNA). By applying these techniques to clinical trial cohorts, they have demonstrated that ctDNA accurately reflects metastatic lesions, predicts resistance to targeted therapies, and reveals the evolving nature of prostate and bladder cancers throughout systemic treatment.
In addition, Dr. Wyatt chairs the correlative sciences and tumor biobanking efforts for the Canadian Cancer Trial Group (CCTG), where he plays a key role in designing and implementing phase I-III clinical trial protocols across Canada. He also leads the ctDNA screening strategy and molecular tumor board for a landmark multi-center phase 2 umbrella trial in metastatic castration-resistant prostate cancer (NCT03385655, NCT02905318).
Explore more of Dr. Wyatt's research at https://blogs.ubc.ca/wyattlab/
Recent Publications